Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Non-Current Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $693.3 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 11.75% to $693.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $693.3 million through Dec 2025, up 11.75% year-over-year, with the annual reading at $693.3 million for FY2025, 11.75% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $693.3 million at Phathom Pharmaceuticals, up from $651.3 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $693.3 million in Q4 2025, with the low at $103.5 million in Q1 2022.
  • Average Total Non-Current Liabilities over 4 years is $424.5 million, with a median of $486.1 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities soared 127.86% in 2024, then rose 11.75% in 2025.
  • Over 4 years, Total Non-Current Liabilities stood at $232.1 million in 2022, then skyrocketed by 105.45% to $476.9 million in 2023, then surged by 30.09% to $620.4 million in 2024, then rose by 11.75% to $693.3 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $693.3 million, $651.3 million, and $644.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.